Condensed Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue, net:
Core companion animal health	$ 14,515	$ 13,530	$ 46,015	$ 45,811
Other vaccines, pharmaceuticals and products	3,080	3,376	8,820	8,541
Total revenue, net	17,595	16,906	54,835	54,352
Cost of revenue	10,189	10,180	34,607	30,655
Gross profit	7,406	6,726	20,228	23,697
Operating expenses:
Selling and marketing	4,591	4,381	14,554	14,020
Research and development	324	180	1,197	717
General and administrative	2,416	2,192	8,662	7,522
Total operating expenses	7,331	6,753	24,413	22,259
Operating income (loss)	75	(27)	(4,185)	1,438
Interest and other (income) expense, net	93	(16)	134	69
Income (loss) before income taxes	(18)	(11)	(4,319)	1,369
Current tax expense	6	16	71	98
Deferred tax expense (benefit)	(6)	5	(1,553)	457
Total income tax expense (benefit)	0	21	(1,482)	555
Net income (loss)	(18)	(32)	(2,837)	814
Net income (loss) attributable to non-controlling interest	(259)	0	(464)	0
Net income (loss) attributable to Heska Corporation	$ 241	$ (32)	$ (2,373)	$ 814
Basic net income (loss) per share attributable to Heska Corporation	$ 0.04	$ (0.01)	$ (0.41)	$ 0.15
Diluted net income (loss) per share attributable to Heska Corporation	$ 0.04	$ (0.01)	$ (0.41)	$ 0.15
Weighted average outstanding shares used to compute basic net income (loss) per share attributable to Heska Corp.	5,826	5,350	5,727	5,314
Weighted average outstanding shares used to compute diluted net income (loss) per share attributable to Heska Corp	5,865	5,350	5,727	5,503